Company / Cash per Share
ALNYLAM PHARMACEUTICALS, INC. Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$12.82
FY2025
5-year range
$4.27 / $12.82
FY2021-FY2025
Trend
+66.8%
vs FY2024
Sector context
#16 of 205
Health Care
What the data says
Among 205 Health Care companies, ALNYLAM PHARMACEUTICALS, INC. is in the top 8% for cash per share. Cash per Share has fluctuated over the past 10 years, ranging from $2.26 in FY2016 to $12.82 in FY2025.
Based on SEC 10-K filings.
12.82 in FY2025 with a 5-year CAGR of +21.3%. Top quartile in the Health Care sector.
Improved from $6.56 to $12.82 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +23.4%
- 5-Year CAGR
- +21.3%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 205This company $12.82 Sector average $67.98
▼
-81.1% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 66.8% year-over-year.
- Ranks #16 out of 205 companies in the Health Care sector.
- Lowest cash per share in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.82 | +66.8% |
| FY2024 | $7.68 | +17.2% |
| FY2023 | $6.56 | -3.9% |
| FY2022 | $6.82 | +60.0% |
| FY2021 | $4.27 | -12.6% |
| FY2020 | $4.88 | +17.5% |
| FY2019 | $4.15 | -35.9% |
| FY2018 | $6.48 | -9.1% |
| FY2017 | $7.13 | +215.1% |
| FY2016 | $2.26 | +5.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026